In an interview with Targeted OncologyTM, Massimo Cristofanilli, MD, medical oncologist at the Breast Center at Weill Cornell ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

A genetic mutation that fuses two genes drives several different cancer types by forming networks of protein interactions that alter gene expression in cells, a study by UT Southwestern Medical Center ...

Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

This trial evaluated the efficacy and safety of Johnson & Johnson’s (J&J) Akeega, which includes Zejula (niraparib), a highly ...

Understand the role of acquired mutations in resistance to endocrine ... continue to evaluate therapeutics for germline and somatic pathogenic variants. Genomic Signatures in Early-stage ER+ Breast ...

BRCAness refers to tumors that mimic BRCA1/2 mutation behavior, making them vulnerable to DNA-damaging treatments like PARP ...

There were 22 men with progressive mCRPC enrolled, the median age at enrollment was 66 years (range 52-80), the median PSA at original diagnosis was 82 ng/mL (range 5-3,648), 55% had a Gleason score 9 ...